Clin Hematol Int. 2024 May 6;6(2):46-50. doi: 10.46989/001c.116800. eCollection 2024.
ABSTRACT
We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the treatment with anti-B cell maturation antigen (BCMA)xCD3 bispecific antibody proved to be feasible, without unexpected side effects. Increased attention to infectious risk is crucial for these doubly fragile patients.
PMID:38817306 | PMC:PMC11108588 | DOI:10.46989/001c.116800